Anti Gd1a Igm Antibody Positivity C5676716
IgM antibodies against GD1a gangliosides, often indicating recent immune activation. Associated with acute neuropathy and may occur following infections. Typically managed with immunotherapy.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Diplopia
Generalized symptoms
(neurologic)Significant symptoms that substantially affect daily functioning.
Frequency: Varies
Paresthesia
(neurologic)Sensory loss
(neurologic)Gait instability
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Drug therapy and clinical monitoring
Active treatment with regular monitoring by a healthcare provider is recommended.
Intravenous Immunoglobulin (IVIG)
IVIG is the preferred first-line treatment for IgM anti-ganglioside antibody-associated disorders. It neutralizes pathogenic antibodies, blocks macrophage Fc receptor binding, and modulates the innate immune response.
Plasma Exchange
Therapeutic plasma exchange rapidly removes circulating IgM anti-ganglioside antibodies. This treatment is particularly beneficial during acute exacerbations or when neurological deficits are rapidly progressing.
Additional treatment options
Rituximab
Rituximab targets CD20-positive B cells to suppress IgM antibody production. Clinical evidence supports its use in IgM anti-ganglioside neuropathies, particularly in patients with inadequate response to first-line therapies.
medicationPain Management
Neuropathic pain associated with anti-ganglioside antibodies may require adjuvant analgesics such as gabapentinoids or antidepressants. Comprehensive pain management improves quality of life and functional status.
complementaryLongitudinal Neurological Assessment
Regular neurological examinations tracking motor strength, sensory function, and autonomic symptoms. Structured assessments using validated scales help quantify disease progression and treatment efficacy.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Anti Gd1a Igm Antibody Positivity C5676716?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016.
Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: autoantibody findings and their clinical associations. J Neurol Neurosurg Psychiatry. 2013.
Verkman AS, Smith AJ, Raphemot R. Ganglioside antibody-associated neuropathy: clinical features and treatment outcomes. Neurology. 2018.
Dimachkie MM, Barohn RJ, Katirji B. Infectious and immune-mediated neuropathies: a comprehensive review. Muscle Nerve. 2020.
Medication Comparisons
Compare medications used to treat Anti Gd1a Igm Antibody Positivity C5676716. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy